- GlobeNewswire•5 days ago
First Phase 2 study will evaluate prime-boost vaccine approach in elderly population COPENHAGEN, Denmark, October 18, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of ...
- GlobeNewswire•13 days agoBavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC and Ipilimumab in Patients with Localized Prostate Cancer
Trial is being conducted as part of clinical collaboration with Bristol-Myers Squibb COPENHAGEN, Denmark, October 10, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation ...
- GlobeNewswire•24 days agoBavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV Symposium
COPENHAGEN, Denmark, September 29, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the presentation of data from a Phase 1 study of its novel, broad spectrum RSV (respiratory syncytial ...
Bavarian Nordic A/S (BAVA.CO)
Copenhagen - Copenhagen Delayed Price. Currency in DKK
|Day's Range||234.00 - 238.00|
|52wk Range||197.00 - 361.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-33.50|
|Avg Vol (3m)||111,691|
|Dividend & Yield||N/A (N/A)|